14. SEGMENTS

12 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:

	Fiscal Years Ended March 31,
	2015			2014
Revenues:
Aethlon	$	762,417		$	1,623,769
ESI		–			–
Total Revenues	$	762,417		$	1,623,769
Operating Losses:
Aethlon	$	(3,081,169	)	$	(2,651,863	)
ESI		(911,684	)		(404,065	)
Total Operating Loss	$	(3,992,853	)	$	(3,055,928	)
Net Losses:
Aethlon	$	(6,087,810	)	$	(13,357,232	)
ESI		(911,684	)		(81,730	)
Net Loss Before Non-Controlling Interests	$	(6,979,494	)	$	(13,438,962	)
Cash:
Aethlon	$	721,689		$	208,259
ESI		133,907			1,042,020
Total Cash	$	855,596		$	1,250,279
Total Assets:
Aethlon	$	1,159,910		$	597,026
ESI		220,678			1,098,076
Total Assets	$	1,380,588		$	1,695,102
Capital Expenditures:
Aethlon	$	–		$	37,313
ESI		–			58,743
Capital Expenditures	$	–		$	96,056
Depreciation and Amortization:
Aethlon	$	17,770		$	11,549
ESI		19,582			9,538
Total Depreciation and Amortization	$	37,352		$	21,087
Interest Expense:
Aethlon	$	349,923		$	1,282,638
ESI		–			4,583
Total Interest Expense	$	349,923		$	1,287,221